• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥大细胞与脂类介质在肺血管重构中的病理生理学作用。

Pathophysiological Involvement of Mast Cells and the Lipid Mediators in Pulmonary Vascular Remodeling.

机构信息

Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku 160-8582, Tokyo, Japan.

Department of Cardiology, Tokyo Dental College Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa 272-8513, Chiba, Japan.

出版信息

Int J Mol Sci. 2023 Apr 1;24(7):6619. doi: 10.3390/ijms24076619.

DOI:10.3390/ijms24076619
PMID:37047587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10094825/
Abstract

Mast cells are responsible for IgE-dependent allergic responses, but they also produce various bioactive mediators and contribute to the pathogenesis of various cardiovascular diseases, including pulmonary hypertension (PH). The importance of lipid mediators in the pathogenesis of PH has become evident in recent years, as exemplified by prostaglandin I2, the most central therapeutic target in pulmonary arterial hypertension. New bioactive lipids other than eicosanoids have also been identified that are associated with the pathogenesis of PH. However, it remains largely unknown how mast cell-derived lipid mediators are involved in pulmonary vascular remodeling. Recently, it has been demonstrated that mast cells produce epoxidized n-3 fatty acid (n-3 epoxides) in a degranulation-independent manner, and that n-3 epoxides produced by mast cells regulate the abnormal activation of pulmonary fibroblasts and suppress the progression of pulmonary vascular remodeling. This review summarizes the role of mast cells and bioactive lipids in the pathogenesis of PH. In addition, we introduce the pathophysiological role and therapeutic potential of n-3 epoxides, a mast cell-derived novel lipid mediator, in the pulmonary vascular remodeling in PH. Further knowledge of mast cells and lipid mediators is expected to lead to the development of innovative therapies targeting pulmonary vascular remodeling.

摘要

肥大细胞负责 IgE 依赖性过敏反应,但它们也产生各种生物活性介质,并有助于各种心血管疾病的发病机制,包括肺动脉高压 (PH)。近年来,脂类介质在 PH 发病机制中的重要性已经显而易见,例如前列腺素 I2 是肺动脉高压的最核心治疗靶点。除了类二十烷酸之外,还发现了与 PH 发病机制相关的其他新的生物活性脂质。然而,肥大细胞衍生的脂质介质如何参与肺血管重塑在很大程度上仍然未知。最近已经证明,肥大细胞以脱颗粒非依赖性的方式产生环氧-n-3 脂肪酸 (n-3 环氧化物),并且由肥大细胞产生的 n-3 环氧化物调节肺成纤维细胞的异常激活并抑制肺血管重塑的进展。这篇综述总结了肥大细胞和生物活性脂质在 PH 发病机制中的作用。此外,我们介绍了 n-3 环氧化物作为一种肥大细胞衍生的新型脂质介质在 PH 中肺血管重塑的病理生理作用和治疗潜力。进一步了解肥大细胞和脂质介质有望导致针对肺血管重塑的创新治疗方法的发展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e216/10094825/3eb0b0e44671/ijms-24-06619-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e216/10094825/0bbea6899e8f/ijms-24-06619-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e216/10094825/3eb0b0e44671/ijms-24-06619-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e216/10094825/0bbea6899e8f/ijms-24-06619-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e216/10094825/3eb0b0e44671/ijms-24-06619-g002.jpg

相似文献

1
Pathophysiological Involvement of Mast Cells and the Lipid Mediators in Pulmonary Vascular Remodeling.肥大细胞与脂类介质在肺血管重构中的病理生理学作用。
Int J Mol Sci. 2023 Apr 1;24(7):6619. doi: 10.3390/ijms24076619.
2
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
3
p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics.p38 MAPK 信号通路在慢性阻塞性肺疾病发病机制及抑制剂治疗中的作用
Cell Commun Signal. 2023 Nov 2;21(1):314. doi: 10.1186/s12964-023-01337-4.
4
The nitrofen/bisdiamine murine model of congenital diaphragmatic hernia has a pulmonary hypertension vascular phenotype consistent with human CDH.先天性膈疝的硝芬/双二胺小鼠模型具有与人类先天性膈疝一致的肺动脉高压血管表型。
Am J Physiol Lung Cell Mol Physiol. 2025 Jul 1;329(1):L48-L60. doi: 10.1152/ajplung.00233.2024. Epub 2025 May 30.
5
Short-Term Memory Impairment短期记忆障碍
6
Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis.用于治疗季节性和常年性过敏性结膜炎的局部用抗组胺药和肥大细胞稳定剂。
Cochrane Database Syst Rev. 2015 Jun 1;2015(6):CD009566. doi: 10.1002/14651858.CD009566.pub2.
7
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.抗抑郁药治疗成人慢性疼痛的疼痛管理:一项网络荟萃分析。
Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948.
8
Systemic Inflammatory Response Syndrome全身炎症反应综合征
9
LOXL2 inhibition ameliorates pulmonary artery remodeling in pulmonary hypertension.LOXL2 抑制可改善肺动脉高压中的肺动脉重构。
Am J Physiol Lung Cell Mol Physiol. 2024 Oct 1;327(4):L423-L438. doi: 10.1152/ajplung.00327.2023. Epub 2024 Jul 16.
10
Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis.抗血管内皮生长因子药物与激光光凝术治疗糖尿病视网膜病变的比较:系统评价与经济分析
Health Technol Assess. 2025 May 7:1-16. doi: 10.3310/KRWP1264.

引用本文的文献

1
Vascular Remodeling: The Multicellular Mechanisms of Pulmonary Hypertension.血管重塑:肺动脉高压的多细胞机制
Int J Mol Sci. 2025 Apr 30;26(9):4265. doi: 10.3390/ijms26094265.
2
Advances and applications of biosensors in pulmonary hypertension.生物传感器在肺动脉高压中的进展与应用
Respir Res. 2025 Apr 15;26(1):147. doi: 10.1186/s12931-025-03221-w.
3
A comprehensive analysis of genes associated with hypoxia and cuproptosis in pulmonary arterial hypertension using machine learning methods and immune infiltration analysis: is a key gene in the cuproptosis process.

本文引用的文献

1
Regulatory Roles of Phospholipase A Enzymes and Bioactive Lipids in Mast Cell Biology.磷脂酶 A 酶和生物活性脂质在肥大细胞生物学中的调控作用。
Front Immunol. 2022 Jun 27;13:923265. doi: 10.3389/fimmu.2022.923265. eCollection 2022.
2
Maresin 1 intervention reverses experimental pulmonary arterial hypertension in mice.马雷辛 1 干预可逆转实验性肺动脉高压小鼠模型。
Br J Pharmacol. 2022 Nov;179(22):5132-5147. doi: 10.1111/bph.15906. Epub 2022 Aug 9.
3
Integrated bioinformatics analysis reveals marker genes and immune infiltration for pulmonary arterial hypertension.
使用机器学习方法和免疫浸润分析对肺动脉高压中与缺氧和铜死亡相关基因的综合分析:是铜死亡过程中的关键基因。
Front Med (Lausanne). 2024 Sep 26;11:1435068. doi: 10.3389/fmed.2024.1435068. eCollection 2024.
4
Immunotherapy for Pulmonary Arterial Hypertension: From the Pathogenesis to Clinical Management.肺动脉高压的免疫治疗:从发病机制到临床管理。
Int J Mol Sci. 2024 Aug 1;25(15):8427. doi: 10.3390/ijms25158427.
5
CC chemokines Modulate Immune responses in Pulmonary Hypertension.CC 趋化因子调节肺动脉高压中的免疫反应。
J Adv Res. 2024 Sep;63:171-186. doi: 10.1016/j.jare.2023.10.015. Epub 2023 Nov 4.
综合生物信息学分析揭示了肺动脉高压的标记基因和免疫浸润。
Sci Rep. 2022 Jun 16;12(1):10154. doi: 10.1038/s41598-022-14307-6.
4
Omega-3 fatty acid epoxides produced by PAF-AH2 in mast cells regulate pulmonary vascular remodeling.肥大细胞中 PAF-AH2 产生的ω-3 脂肪酸环氧化物调节肺血管重塑。
Nat Commun. 2022 May 31;13(1):3013. doi: 10.1038/s41467-022-30621-z.
5
Qualitative and Quantitative Effects of Fatty Acids Involved in Heart Diseases.与心脏病相关的脂肪酸的定性和定量影响。
Metabolites. 2022 Feb 25;12(3):210. doi: 10.3390/metabo12030210.
6
Dysregulated Immunity in Pulmonary Hypertension: From Companion to Composer.肺动脉高压中失调的免疫:从伴随者到主导者。
Front Physiol. 2022 Feb 17;13:819145. doi: 10.3389/fphys.2022.819145. eCollection 2022.
7
Vascular Remodeling in Pulmonary Arterial Hypertension: The Potential Involvement of Innate and Adaptive Immunity.肺动脉高压中的血管重塑:固有免疫和适应性免疫的潜在作用
Front Med (Lausanne). 2021 Dec 22;8:806899. doi: 10.3389/fmed.2021.806899. eCollection 2021.
8
The physiological basis of pulmonary arterial hypertension.肺动脉高压的生理学基础。
Eur Respir J. 2022 Jun 16;59(6). doi: 10.1183/13993003.02334-2021. Print 2022 Jun.
9
Resolvin E1 Attenuates Pulmonary Hypertension by Suppressing Wnt7a/β-Catenin Signaling.解析 E1 通过抑制 Wnt7a/β-连环蛋白信号通路减轻肺动脉高压。
Hypertension. 2021 Dec;78(6):1914-1926. doi: 10.1161/HYPERTENSIONAHA.121.17809. Epub 2021 Oct 25.
10
Innovative Anti-Inflammatory and Pro-resolving Strategies for Pulmonary Hypertension: High Blood Pressure Research Council of Australia Award 2019.创新性抗炎和促解决策略治疗肺动脉高压:2019 年澳大利亚高血压研究委员会奖。
Hypertension. 2021 Nov;78(5):1168-1184. doi: 10.1161/HYPERTENSIONAHA.120.14525. Epub 2021 Sep 27.